Pulmonary Rehabilitation in Interstitial Lung Disease

Status Active, not recruiting

Clinical Trial Summary

Interstitial lung disease (ILD) is a highly disabling group of conditions including idiopathic pulmonary fibrosis (IPF), acute and chronic interstitial pneumonias, connective tissue diseases and sarcoidosis. People with ILD frequently experience breathlessness on exertion, which limits their ability to undertake daily activities. People with ILD report very poor quality of life due to low levels of physical functioning and vitality, and high levels of breathlessness and fatigue. There are few treatments for ILD and those that are available have limited impact on quality of life.

The aim of this study is to assess the effects of Pulmonary Rehabilitation, which consists of specialised exercise training for people with lung disease, on exercise capacity and quality of life in people with ILD. We hypothesis that exercise training will result in reduced dyspnoea, improved exercise tolerance and enhanced quality of life.

Clinical Trial Description

Interstitial lung disease (ILD) is a highly disabling group of conditions including idiopathic pulmonary fibrosis (IPF), acute and chronic interstitial pneumonias, connective tissue diseases and sarcoidosis. People with ILD frequently experience breathlessness on exertion, which limits their ability to undertake daily activities and reduces health-related quality of life.Available treatments for ILD have proved largely ineffective, offering no improvement in survival and demonstrating only limited impact on quality of life.

Aims of the Research

1. Evaluate the effects of Pulmonary Rehabilitation on exercise capacity and quality of life in patients with ILD

2. Determine the physiological response to Pulmonary Rehabilitation in patients with ILD

3. Determine the relationship between the aetiology and severity of ILD and the effects of Pulmonary Rehabilitation.

Comparisons: 8 weeks exercise training compared to control group (maximal exercise capacity, functional exercise capacity, dyspnoea, quality of life). ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00168285
Study type	Interventional
Source	The Alfred
Contact
Status	Active, not recruiting
Phase	N/A
Start date	March 2005
Completion date	May 2007

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT04905693` - Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis	Phase 3
Recruiting	`NCT05631132` - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?	N/A
Recruiting	`NCT05417776` - Collagen-targeted PET Imaging for Early Interstitial Lung Disease	Phase 2
Not yet recruiting	`NCT04089826` - Long Term Oxygen Therapy in Patients With Interstitial Lung Disease
Recruiting	`NCT03467880` - Multicenter Study of Impulse Oscillometry in Chinese	N/A
Completed	`NCT00883129` - Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)	Phase 2
Completed	`NCT00362739` - Blood Collection From Individuals With Lung Disease for Genetic Studies	N/A
Recruiting	`NCT06133998` - Effects of Incentive Spirometry With and Without Aerobic Exercises in Interstitial Lung Disease	N/A
Active, not recruiting	`NCT03485378` - Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease	N/A
Recruiting	`NCT04098094` - Outcomes of RV Dysfunction in Acute Exacerbation of Chronic Respiratory Diseases
Recruiting	`NCT03400839` - Best Clinical Endpoints That Likely Induce Worse Prognosis in Interstitial Lung Diseases
Terminated	`NCT02633293` - An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE	Phase 2/Phase 3
Enrolling by invitation	`NCT05001009` - Goals of Care Conversations Study	N/A
Active, not recruiting	`NCT05068869` - Digital Outpatient Services	N/A
Active, not recruiting	`NCT03727568` - Study Comparing Two Different Methods of Cryobiopsy in the Interstitial Lung Diseases	N/A
Recruiting	`NCT06046547` - Integrating Palliative Care Education in Pulmonary Rehabilitation	N/A
Completed	`NCT04946708` - Virtual Exercise Program in Interstitial Lung Disease (ILD) Patients	N/A
Recruiting	`NCT04139356` - The Effect of Spontaneous Respiration on Pulse-oximetry Measurements	N/A
Recruiting	`NCT03726398` - CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH	Phase 2/Phase 3
Active, not recruiting	`NCT03295279` - WTC Chest CT Imaging Archive

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.